Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liang, Yu ^a   Zhu, Fengyu ^a   Zhang, Haojie ^b   Chen, Demeng ^c   Zhang, Xiuhong ^a   Gao, Qian ^a   Li, Yang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; APOPTOSIS; BLADDER TUMOR; CANCER STEM CELL; CELL PROLIFERATION; CYTOLOGY; DISEASE EXACERBATION; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; MALE; MICE; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; URINARY BLADDER NEOPLASMS;

EID: 84977103924     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29479     Document Type: Article

References (40)

1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin 65, 87-108, doi: 10.3322/caac.21262 (2015).
2. Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J Clin 66, 115-132, doi: 10.3322/caac.21338 (2016).
3. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64, 639-653, doi: 10.1016/j.eururo.2013.06.003 (2013).
4. Kaufman, D. S., Shipley, W. U., Feldman, A. S. Bladder cancer. Lancet 374, 239-249, doi: 10.1016/S0140-6736(09)60491-8 (2009).
5. Parekh, D. J., Bochner, B. H., Dalbagni, G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24, 5519-5527, doi: 10.1200/JCO.2006.08.5431 (2006).
6. Malkowicz, S. B. et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 69, 3-16, doi: 10.1016/j.urology.2006.10.040 (2007).
7. Knowles, M. A., Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature reviews. Cancer 15, 25-41, doi: 10.1038/nrc3817 (2015).
8. Biernacka, A., Dobaczewski, M., Frangogiannis, N. G. TGF-beta signaling in fibrosis. Growth factors 29, 196-202, doi: 10.3109/08977194.2011.595714 (2011).
9. Moustakas, A., Heldin, C. H. The regulation of TGFbeta signal transduction. Development 136, 3699-3714, doi: 10.1242/dev.030338 (2009).
10. Horbelt, D., Denkis, A., Knaus, P. A portrait of Transforming Growth Factor beta superfamily signalling: Background matters. Int J Biochem Cell Biol 44, 469-474, doi: 10.1016/j.biocel.2011.12.013 (2012).
11. Song, J. EMT or apoptosis: a decision for TGF-beta. Cell Res 17, 289-290, doi: 10.1038/cr.2007.25 (2007).
12. Derynck, R., Akhurst, R. J., Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29, 117-129, doi: 10.1038/ng1001-117 (2001).
13. Wei, H. et al. Genetic variations in the transforming growth factor beta pathway as predictors of bladder cancer risk. PLoS One 7, e51758, doi: 10.1371/journal.pone.0051758 (2012).
14. Fan, Y. et al. TGF-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 1531-1541, doi: 10.1158/1078-0432.CCR-13-1455 (2014).
15. Williams, P. D., Lee, J. K., Theodorescu, D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 10, 838-846 (2008).
16. Bertram, J. S., Craig, A. W. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 8, 587-594 (1972).
17. Van Batavia, J. et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol 16, 982-991, 981-985, doi: 10.1038/ncb3038 (2014).
18. Horiguchi, K. et al. Role of Ras signaling in the induction of snail by transforming growth factor-beta. The Journal of biological chemistry 284, 245-253, doi: 10.1074/jbc.M804777200 (2009).
19. Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209-213, doi: 10.1038/nature14034 (2015).
20. Leivonen, S. K., Kahari, V. M. Transforming growth factor-beta signaling in cancer invasion and metastasis. International journal of cancer. Journal international du cancer 121, 2119-2124, doi: 10.1002/ijc.23113 (2007).
21. Vogt, J., Traynor, R., Sapkota, G. P. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal 23, 1831-1842, doi: 10.1016/j.cellsig.2011.06.019 (2011).
22. Chen, D., Jarrell, A., Guo, C., Lang, R., Atit, R. Dermal beta-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. Development 139, 1522-1533, doi: 10.1242/dev.076463 (2012).
23. Cheng, Y., Tu, Y., Liang, P. Promoter Methylated Tumor Suppressor Genes in Glioma. Cancer Translational Medicine 1, 8, doi: 10.4103/2395-3977.163803 (2015).
24. Sun, S., Xu, A., Yang, G., Cheng, Y. Galanin is a novel epigenetic silenced functional tumor suppressor in renal cell carcinoma. Cancer Translational Medicine 1, 5, doi: 10.4103/2395-3977.172861 (2015).
25. Chen, D., Dai, C., Jiang, Y. Histone H2A and H2B Deubiquitinase in Developmental Disease and Cancer. Cancer Translational Medicine 1, 6, doi: 10.4103/2395-3977.168578 (2015).
26. Pei, M., Chen, D., Li, J., Wei, L. Histone deacetylase 4 promotes TGF-beta1-induced synovium-derived stem cell chondrogenesis but inhibits chondrogenically differentiated stem cell hypertrophy. Differentiation 78, 260-268, doi: 10.1016/j.diff.2009.08.001 (2009).
27. Yao, R. et al. Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine. Neoplasia 6, 569-577, doi: 10.1593/neo.04223 (2004).
28. Hung, T. T., Wang, H., Kingsley, E. A., Risbridger, G. P., Russell, P. J. Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. Cancer Lett 265, 27-38, doi: 10.1016/j.canlet.2008.02.034 (2008).
29. Li, Y. et al. Inhibition of TGF-beta receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase. International urology and nephrology 42, 315-323, doi: 10.1007/s11255-009-9620-3 (2010).
30. Neuzillet, C. et al. Targeting the TGFbeta pathway for cancer therapy. Pharmacology & therapeutics 147, 22-31, doi: 10.1016/j. pharmthera.2014.11.001 (2015).
31. Ghosh, M., Brancato, S. J., Agarwal, P. K., Apolo, A. B. Targeted therapies in urothelial carcinoma. Current opinion in oncology 26, 305-320, doi: 10.1097/CCO.0000000000000064 (2014).
32. Chen, H. H., Zhao, S., Song, J. G. TGF-beta1 suppresses apoptosis via differential regulation of MAP kinases and ceramide production. Cell death and differentiation 10, 516-527, doi: 10.1038/sj.cdd.4401171 (2003).
33. Peng, L., Hu, Y., Chen, D., Jiao, S., Sun, S. Ubiquitin specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma. Oncotarget 7, 10, doi: 10.18632/oncotarget.9751 (2016).
34. Oshimori, N., Oristian, D., Fuchs, E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963-976, doi: 10.1016/j.cell.2015.01.043 (2015).
35. Wang, X. et al. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med 13, 142-164, doi: 10.1016/S2095-4964(15)60171-6 (2015).
36. Xu, J., Lamouille, S., Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19, 156-172, doi: 10.1038/cr.2009.5 (2009).
37. Takata, T., Motoo, Y., Tomosugi, N. Effect of Saikokeishito, a Kampo medicine, on hydrogen peroxide-induced premature senescence of normal human dermal fibroblasts. J Integr Med 12, 495-503, doi: 10.1016/S2095-4964(14)60052-2 (2014).
38. Shin, K. et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer cell 26, 521-533, doi: 10.1016/j.ccell.2014.09.001 (2014).
39. Li, Y. et al. The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget 6, 10195-10206 (2015).
40. Li, Y. et al. MAFIP is a tumor suppressor in cervical cancer that inhibits activation of the nuclear factor-kappa B pathway. Cancer Sci 102, 2043-2050, doi: 10.1111/j.1349-7006.2011.02061.x (2011).